Drug intelligence / Profile preview

betamethasone + ceftazidime + prednisolone + sulfasalazine

Development stage
Unknown
Lead developer
Merck
Modality
Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Administration
Oral, Intravenous, Intramuscular, Topical, Rectal, Ophthalmic
01

Overview

This is a combination drug consisting of four active pharmaceutical ingredients: - **Betamethasone** is a potent synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties. It modulates gene expression to suppress immune responses and reduce inflammation[5][3]. - **Ceftazidime** is a third-generation cephalosporin beta-lactam antibiotic that acts by inhibiting bacterial cell wall synthesis, primarily targeting penicillin-binding protein 3 (PBP3), leading to bactericidal activity against susceptible Gram-negative bacteria[2][9]. - **Prednisolone** is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive effects, similar in action to betamethasone. - **Sulfasalazine (also known as salazosulfapyridine)** is an anti-inflammatory disease-modifying antirheumatic drug (DMARD) used mainly in the treatment of ulcerative colitis, Crohn's disease, and rheumatoid arthritis. It consists of 5-aminosalicylic acid linked to sulfapyridine; its mechanism involves both local anti-inflammatory effects in the colon and systemic immunomodulation[6][8]. This specific four-drug combination does not correspond to any widely recognized or marketed pharmaceutical product but represents the co-administration of these agents for their respective indications.

Other names
betamethasone + ceftazidime + prednisolone + salazosulfapyridine
02

Targets

COXPBP (Penicillin-binding protein family)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on betamethasone + ceftazidime + prednisolone + sulfasalazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on betamethasone + ceftazidime + prednisolone + sulfasalazine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call